HemoBioTech to showcase pre-clinical results of human blood substitute
HemoBioTech, a biopharmaceutical company focused on developing the first commercial substitute for human blood, has gathered results from a pre-clinical study of its HemoTech blood substitute product in patients undergoing percutaneous coronary intervention through angioplasty and stent implantation.
In the ex vivo human study, HemoTech showed reduced platelet aggregation, one of the major complications associated with PCI procedures, HemoBioTech said in a release.
The Dallas-based company plans to initiate clinical trials in India, according to Arthur Bollon, chairman and CEO of HemoBioTech.
HemoBioTech and Texas Tech University Health Sciences Center are scheduled to present the study’s findings at the 11th international symposium on Blood Substitutes in Beijing, China, Oct.19-22; and the combined 45th annual meeting of the Japanese Society for Artificial Organs and 2nd congress of the International Federation for Artificial Organs in Osaka, Japan, Oct. 28-31.
In the ex vivo human study, HemoTech showed reduced platelet aggregation, one of the major complications associated with PCI procedures, HemoBioTech said in a release.
The Dallas-based company plans to initiate clinical trials in India, according to Arthur Bollon, chairman and CEO of HemoBioTech.
HemoBioTech and Texas Tech University Health Sciences Center are scheduled to present the study’s findings at the 11th international symposium on Blood Substitutes in Beijing, China, Oct.19-22; and the combined 45th annual meeting of the Japanese Society for Artificial Organs and 2nd congress of the International Federation for Artificial Organs in Osaka, Japan, Oct. 28-31.